- Home
- PDFS vs XNCR Comparison
PDFS vs XNCR Comparison
Compare PDFS & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PDFS | XNCR |
|---|---|---|
| Founded | 1992 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.0B |
| IPO Year | 2000 | 2013 |
Fundamental Metrics
Financial Performance| Metric | PDFS | XNCR |
|---|---|---|
| Price | $42.33 | $30.54 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 14 |
| Target Price | ★ $60.75 | $41.58 |
| AVG Volume (30 Days) | 563.0K | ★ 1.5M |
| Earning Date | 11-05-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 65.36 |
| EPS | ★ 0.22 | N/A |
| Revenue | N/A | ★ $125,576,000.00 |
| Revenue This Year | $20.46 | $18.52 |
| Revenue Next Year | $20.66 | N/A |
| P/E Ratio | $178.00 | ★ N/A |
| Revenue Growth | N/A | ★ 13.65 |
| 52 Week Low | $23.55 | $10.38 |
| 52 Week High | $71.69 | $33.60 |
Technical Indicators
Market Signals| Indicator | PDFS | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 43.83 | 67.95 |
| Support Level | $39.79 | $22.80 |
| Resistance Level | $48.78 | $30.61 |
| Average True Range (ATR) | 2.60 | 1.69 |
| MACD | -0.20 | 0.52 |
| Stochastic Oscillator | 32.75 | 69.39 |
Price Performance
Historical ComparisonAbout PDFS PDF Solutions Inc.
PDF Solutions Inc provides products and services designed to empower organizations across the semiconductor and electronics ecosystem to connect, collect, manage, and analyze data about design, equipment, manufacturing, and test to improve the yield and quality of their products and operational efficiency. The Company's products, services, and solutions include proprietary software, physical intellectual property (IP) for integrated circuit (IC) designs, electrical measurement hardware tools, methodologies, and professional services.
About XNCR Xencor Inc.
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.